Earnings summary
4D Molecular Therapeutics, Inc. Q2 2025 results
Snapshot
4D Molecular Therapeutics, Inc. reported $0M of revenue in Q2 2025, up 200.0% year over year, with diluted EPS of $-0.98 and an operating margin of -396373.3%.
- Revenue
- $0M
- YoY growth
- +200.0%
- Diluted EPS
- $-0.98
- Operating margin
- -396373.3%
$0M
Revenue
+200.0%
YoY growth
$-0.98
Diluted EPS
-396373.3%
Operating margin